Your browser doesn't support javascript.
loading
Volatile organic compounds in human matrices as lung cancer biomarkers: a systematic review.
Janssens, Eline; van Meerbeeck, Jan P; Lamote, Kevin.
Afiliación
  • Janssens E; Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Wilrijk, Belgium; Infla-Med Centre of Excellence, University of Antwerp, Wilrijk, Belgium.
  • van Meerbeeck JP; Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Wilrijk, Belgium; Infla-Med Centre of Excellence, University of Antwerp, Wilrijk, Belgium; Department of Internal Medicine, Ghent University, Ghent, Belgium; Pulmonology and Thoracic Oncology, Antwerp University Hospital, Edegem, Belgium.
  • Lamote K; Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Wilrijk, Belgium; Infla-Med Centre of Excellence, University of Antwerp, Wilrijk, Belgium; Department of Internal Medicine, Ghent University, Ghent, Belgium. Electronic address: kevin.lamote@uantwerpen.be.
Crit Rev Oncol Hematol ; 153: 103037, 2020 Sep.
Article en En | MEDLINE | ID: mdl-32771940
Volatile organic compounds (VOCs) have shown potential as non-invasive breath biomarkers for lung cancer, but their unclear biological origin currently limits clinical applications. This systematic review explores headspace analysis of VOCs in patient-derived body fluids and lung cancer cell lines to pinpoint lung cancer-specific VOCs and uncover their biological origin. A search was performed in the databases MEDLINE and Web of Science. Twenty-two articles were included in this systematic review. Since there is no standardised approach to analyse VOCs, a plethora of techniques and matrices/cell lines were explored, which is reflected in the various VOCs identified. However, comparing VOCs in the headspace of urine, blood and pleural effusions from patients and lung cancer cell lines showed some overlapping VOCs, indicating their potential use in lung cancer diagnosis. This review demonstrates that VOCs are promising biomarkers for lung cancer. However, due to lack of inter-matrix consensus, standardised prospective trials will have to be conducted to validate clinically relevant biomarkers.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos Orgánicos Volátiles / Neoplasias Pulmonares Tipo de estudio: Observational_studies / Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Crit Rev Oncol Hematol Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Bélgica Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos Orgánicos Volátiles / Neoplasias Pulmonares Tipo de estudio: Observational_studies / Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Crit Rev Oncol Hematol Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Bélgica Pais de publicación: Países Bajos